<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456714</url>
  </required_header>
  <id_info>
    <org_study_id>volgt</org_study_id>
    <nct_id>NCT02456714</nct_id>
  </id_info>
  <brief_title>Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma</brief_title>
  <acronym>4CC</acronym>
  <official_title>Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cholangiocarcinoma, is a malignant gastrointestinal tumor of low incidence with a poor
      prognosis. Chemotherapy is the most common treatment for advanced disease. On the basis of a
      phase III clinical study, cisplatin plus gemcitabine is considered standard first-line
      treatment in advanced cholangiocarcinoma patients, but there is no established second line
      therapy.

      Since fluorouracil and leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX)
      appears to be safe and demonstrated efficacy in clinical studies of advanced pancreatic
      cancer, colorectal cancer and a phase I study in cholangiocarcinoma, this combination could
      be an effective second-line treatment for patients with advanced cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pilot study: toxicity</measure>
    <time_frame>24 weeks</time_frame>
    <description>number of adverse events in accordance with CTCAEv4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>phase II: the response rate</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pilot study: the response rate</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pilot study: time to progression.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pilot study: the overall survival</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pilot study: quality of life</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phase II: toxicity during the treatment period and 30 days after the treatment.</measure>
    <time_frame>24 weeks</time_frame>
    <description>number of adverse events in accordance with CTCAEv4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phase II: time to progression.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phase II: the overall survival.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phase II: quality of life</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Progressive cholangiocarcinoma, second line treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRINOX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <arm_group_label>Progressive cholangiocarcinoma, second line treatment</arm_group_label>
    <other_name>Second line treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of cholangiocarcinoma.

          -  Metastatic disease or irresectable locally advanced cholangiocarcinoma.

          -  Measurable disease according RECIST criteria version 1.1.

          -  Age from 18 to 75 year.

          -  WHO/ECOG performance status 0-2.

          -  Patients who received at least 3 cycles of gemcitabine/cisplatin in the first line.

          -  Adequate hematological function (WBC &gt; 3.0 x 109/L, platelets &gt; 100 x109/L)

          -  Adequate hepatic function (bilirubin ≤ 1.5 x upper normal limit (ULN); ALAT or ASAT
             &lt;5x ULN in case of liver metastases and &lt; 2.5 x ULN in absence of liver metastases.

          -  Adequate renal function (creatinine clearance &gt; 60 ml/min; creatinine &lt;120 µmol/L)

          -  Absence of cardiac insufficiency, chest pain (not medically controlled) and myocardial
             infarction in the 12 months preceding study entry.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Concurrent secondary malignancies or other malignancies within 3 years prior to enter
             this study with the exception of non-metastatic basal cell or squamous cell skin
             cancer or carcinoma in situ of the cervix treated by cone-biopsy or resection

          -  Presence of cerebral or meningeal metastases

          -  Contraindication to any of the substances of the planned treatment.

          -  History of chronic diarrhea or colorectal inflammatory conditions, or of unresolved
             occlusion or sub-occlusion for which symptomatic treatment is being administered

          -  Active infection or other serious underlying conditions which may prevent the patient
             from receiving the planned treatment. For example: prolonged unresolved bacterial
             cholangitis with destruction of bile duct branches (e.g. after endoprosthesis
             insertion) or two or more cholangitis in the last 6 months. Patients with other active
             or uncontrolled severe infection, cirrhosis or chronic active hepatitis will be
             excluded.

          -  Presence of cardiac insufficiency, unstable angina pectoris, symptomatic congestive
             heart, failure myocardial infarction 6 months prior to randomization, serious
             uncontrolled cardiac arrhythmia.

          -  Inclusion in another investigational clinical trial

          -  Women who are pregnant, breast-feeding or not using adequate contraceptive

          -  Age younger than 18 or older than 76 years

          -  Individuals under correctional supervision or guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H.J. Klümpen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Wilmink, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>H Klümpen, MD, PhD</last_name>
    <phone>31 20 566 5955</phone>
    <email>h.klumpen@amc.uva.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic medical center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.J. Klumpen, MD</last_name>
      <phone>003120566955</phone>
      <email>trialmedonc@amc.nl</email>
    </contact>
    <investigator>
      <last_name>H.J. Klumpen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Heinz-Josef Klumpen</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>FOLFIRINOX</keyword>
  <keyword>Phase II study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

